Koike Y, Shimamura K, Shudo I, Saito H
Res Commun Chem Pathol Pharmacol. 1979 Apr;24(1):37-47.
Verapamil was given intravenously (10 mg) and orally (120 mg) in six healthy subjects. After intravenous administration, the serum levels in all subjects declined bi-exponentially. Thereupon, pharmacokinetic parameters were calculated using a two-compartment open model. The half-lives of distribution (T 1/2 alpha) and elimination (T 1/2 beta) phases showed 0.23 hour and 4.21 hour on an average respectively. The apparent volume of distribution [Vd (area)] showed 2.51 1/kg and body clearance (C1b) showed 500.64 ml/min on an average. Renal clearance was smaller than normal human creatinine clearance. After oral administration, the time to reach peak blood level (Tmax) was reached within 1.84 hour and the peak serum concentration showed 219.09 ng/ml on an average. The bioavailability was only 22.47% on an average. Verapamil produced a marked prolongation of PQ interval on electrocardiogram and the degree of PQ interval prolongation was closely related to the increase in serum concentration of this compound. QRS, QTc and RR interval were not changed by this compound.
在6名健康受试者中静脉注射(10毫克)和口服(120毫克)维拉帕米。静脉给药后,所有受试者的血清水平呈双指数下降。随后,使用二室开放模型计算药代动力学参数。分布半衰期(T1/2α)和消除半衰期(T1/2β)平均分别为0.23小时和4.21小时。表观分布容积[Vd(面积)]平均为2.51升/千克,机体清除率(C1b)平均为500.64毫升/分钟。肾清除率低于正常人肌酐清除率。口服给药后,1.84小时内达到血药浓度峰值时间(Tmax),血清峰值浓度平均为219.09纳克/毫升。生物利用度平均仅为22.47%。维拉帕米使心电图上的PQ间期明显延长,PQ间期延长程度与该化合物血清浓度升高密切相关。该化合物未改变QRS、QTc和RR间期。